Expression profile of shelterin components in plasma cell disorders. Clinical significance of POT1 overexpression

Blood Cells, Molecules, and Diseases

Volumn 52, Issue 2-3, 2014, Pages 134-139

  Panero, Julieta ^a   Stanganelli, Carmen ^b   Arbelbide, Jorge ^c   Fantl, Dorotea Beatriz ^c   Kohan, Dana ^c   García Rivello, Hernán ^c   Rabinovich, Gabriel A ^d,e   Slavutsky, Irma ^a  

^a ACADEMIA NACIONAL DE MEDICINA   (Argentina)

^b INST DE INVEST HEMATOLOGICAS   (Argentina)

^c HOSPITAL ITALIANO DE BUENOS AIRES   (Argentina)

^d INST DE BIOL Y MED EXPERIMENTAL   (Argentina)

^e UNIVERSIDAD DE BUENOS AIRES   (Argentina)

Author keywords

MGUS; Multiple myeloma; POT1 expression; Telomere associated genes

Indexed keywords

BETA 2 MICROGLOBULIN; CALCIUM; POT1 PROTEIN; PROTEIN; RAP1 PROTEIN; SHELTERIN; TIN2 PROTEIN; TPP1 PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CLINICAL FEATURE; GENE; GENE EXPRESSION; GENE EXPRESSION PROFILING; HEMOSTASIS; HUMAN; MAJOR CLINICAL STUDY; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE MYELOMA; OVERALL SURVIVAL; PLASMA CELL; PLASMA CELL LEUKEMIA; POT1 GENE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RAP1 GENE; REAL TIME POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT; TELOMERE; TIN2 GENE; TPP1 GENE;

MGUS; MULTIPLE MYELOMA; POT1 EXPRESSION; TELOMERE ASSOCIATED GENES;

AGED; AGED, 80 AND OVER; DNA METHYLATION; FOLLOW-UP STUDIES; GALECTIN 1; GENE EXPRESSION PROFILING; HUMANS; MIDDLE AGED; MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE; MULTIPLE MYELOMA; PROGNOSIS; PROMOTER REGIONS, GENETIC; TELOMERASE; TELOMERE-BINDING PROTEINS;

EID: 84891901703     PISSN: 10799796     EISSN: 10960961     Source Type: Journal    
DOI: 10.1016/j.bcmd.2013.10.002     Document Type: Article

References (56)

1. Dimopoulos M., Kyle R., Fermand J.P., Rajkumar S.V., San Miguel J., Chanan-Khan A., Ludwig H., Joshua D., Mehta J., Gertz M., Avet-Loiseau H., Beksaç M., Anderson K.C., Moreau P., Singhal S., Goldschmidt H., Boccadoro M., Kumar S., Giralt S., Munshi N.C., Jagannath S. Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3. Blood 2011, 117:4701-4706.
2. Landgren O., Kyle R.A., Pfeiffer R.M., Katzmann J.A., Caporaso N.E., Hayes R.B., Dispenzieri A., Kumar S., Clark R.J., Baris D., Hoover R., Rajkumar S.V. Monoclonal gammopathy of undetermined significance preceding multiple myeloma: a prospective study. Blood 2009, 113:5412-5417.
3. Mingens Wols H.A., Underhill G.H., Kansas G.S., Witte P.L. The role of bone marrow-derived stromal cells in the maintenance of plasma cell longevity. J. Immunol. 2002, 169:4213-4221.
4. Noll J.E., Williams S.A., Purton L.E., Zannettino A.C.W. Tug of war in the haematopoietic stem cell niche: do myeloma plasma cells compete for the HSC nicheα. Blood Cancer J. 2012, 2:e91.
5. Abroun S., Otsuyama K., Shamsasenjan K., Islam A., Amin J., Iqbal M.S., Gondo T., Asaoku H., Kawano M.M. Galectin-1 supports the survival of CD45RA(-) primary myeloma cells in vitro. Br. J. Haematol. 2008, 142:754-765.
6. Blasco M.A. Telomeres and human disease: ageing, cancer and beyond. Nat. Rev. Genet. 2005, 6:611-622.
7. Cohen S.B., Graham M.E., Lovrecz G.O., Bache N., Robinson P.J., Reddel R.R. Protein composition of catalytically active human telomerase from immortal cells. Science 2007, 315:850-853.
8. Venteicher A.S., Abreu E.B., Meng Z., McCann K.E., Terns R.M., Veenstra T.D., Terns M.P., Artandi S.E. A human telomerase holoenzyme protein required for Cajal body localization and telomere synthesis. Science 2009, 323:644-648.
9. Shiratsuchi M., Muta K., Abe Y., Motomura S., Taguchi F., Takatsuki H., Uike N., Umemura T., Nawata H., Nishimura J. Clinical significance of telomerase activity in multiple myeloma. Cancer 2002, 94:2232-2238.
10. Xu D., Zheng C., Bergenbrant S., Holm G., Björkholm M., Yi Q., Gruber A. Telomerase activity in plasma cell dyscrasias. Br. J. Cancer 2001, 84:621-625.
11. Gahrton G. New therapeutic targets in multiple myeloma. Lancet 2004, 364:1648-1649.
12. Wu K.D., Orme L.M., Shaughnessy J., Jacobson J., Barlogie B., Moore M.A. Telomerase and telomere length in multiple myeloma: correlations with disease heterogeneity, cytogenetic status, and overall survival. Blood 2003, 101:4982-4989.
13. Panero J., Arbelbide J., Fantl D.B., Rivello H.G., Kohan D., Slavutsky I. Altered mRNA expression of telomere-associated genes in monoclonal gammopathy of undetermined significance and multiple myeloma. Mol. Med. 2010, 16:471-478.
14. Guilleret I., Benhattar J. Unusual distribution of DNA methylation within the hTERT CpG island in tissues and cell lines. Biochem. Biophys. Res. Commun. 2004, 325:1037-1043.
15. Daniel M., Peek G.W., Tollefsbol T.O. Regulation of the human catalytic subunit of telomerase (hTERT). Gene 2012, 498:135-146.
16. Palm W., de Lange T. How shelterin protects mammalian telomeres. Annu. Rev. Genet. 2008, 42:301-334.
17. Lei M., Podell E.R., Cech T.R. Structure of human POT1 bound to telomeric single-stranded DNA provides a model for chromosome end-protection. Nat. Struct. Mol. Biol. 2004, 11:1223-1229.
18. Kelleher C., Kurth I., Lingner J. Human protection of telomeres 1 (POT1) is a negative regulator of telomerase activity in vitro. Mol. Cell. Biol. 2005, 25:808-818.
19. Court R., Chapman L., Fairall L., Rhodes D. How the human telomeric proteins TRF1 and TRF2 recognize telomeric DNA: a view from high-resolution crystal structures. EMBO J. 2005, 6:39-45.
20. Sarthy J., Bae N.S., Scrafford J., Baumann P. Human RAP1 inhibits non-homologous end joining at telomeres. EMBO J. 2009, 28:3390-3399.
21. Kabir S., Sfeir A., de Lange T. Taking apart Rap1: an adaptor protein with telomeric and non-telomeric functions. Cell Cycle 2010, 9:4061-4067.
22. Díaz de la Guardia R., Catalina P., Panero J., Elosua C., Pulgarin A., López M.B., Ayllón V., Ligero G., Slavutsky I., Leone P.E. Expression profile of telomere-associated genes in multiple myeloma. J. Cell. Mol. Med. 2012, 16:3009-3021.
23. International Myeloma Working Group Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br. J. Haemtol. 2010, 121:749-757.
24. Durie B.G., Salmon E. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 1975, 36:842-854.
25. Greipp P.R., San Miguel J., Durie B.G., Crowley J.J., Barlogie B., Bladé J., Boccadoro M., Child J.A., Avet-Loiseau H., Kyle R.A., Lahuerta J.J., Ludwig H., Morgan G., Powles R., Shimizu K., Shustik C., Sonneveld P., Tosi P., Turesson I., Westin J. International staging system for multiple myeloma. J. Clin. Oncol. 2005, 23:3412-3420.
26. Klapper W., Krams M., Qian W., Janssen D., Parwaresch R. Telomerase activity in B-cell non-Hodgkin lymphomas is regulated by hTERT transcription and correlated with telomere-binding protein expression but uncoupled from proliferation. Br. J. Cancer 2003, 89:713-719.
27. Poncet D., Belleville A., t'kint de Roodenbeke C., Roborel de Climens A., Ben Simon E., Merle-Beral H., Callet-Bauchu E., Salles G., Sabatier L., Delic J., Gilson E. Changes in the expression of telomere maintenance genes suggest global telomere dysfunction in B-chronic lymphocytic leukemia. Blood 2008, 111:2388-3291.
28. Hu L.H., Chen F.H., Li Y.R., Wang L. Real-time determination of human telomerase reverse transcriptase mRNA in gastric cancer. World J. Gastroenterol. 2004, 10:3514-3517.
29. Cottliar A., Pedrazzini E., Corrado C., Engelberger M.I., Narbaitz M., Slavutsky I. Telomere shortening in patients with plasma cell disorders. Eur. J. Haematol. 2003, 71:334-340.
30. Stanganelli C., Arbelbide J., Fantl D.B., Corrado C., Slavutsky I. DNA methylation analysis of tumor suppressor genes in monoclonal gammopathy of undetermined significance. Ann. Hematol. 2010, 89:191-199.
31. Juszczynski P., Ouyang J., Monti S., Rodig S.J., Takeyama K., Abramson J., Chen W., Kutok J.L., Rabinovich G.A., Shipp M.A. The AP1-dependent secretion of galectin-1 by Reed Sternberg cells fosters immune privilege in classical Hodgkin lymphoma. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:13134-13139.
32. Ilarregui J.M., Croci D.O., Bianco G.A., Toscano M.A., Salatino M., Vermeulen M.E., Geffner J.R., Rabinovich G.A. Tolerogenic signals delivered by dendritic cells to T cells through a galectin-1-driven immunoregulatory circuit involving interleukin 27 and interleukin 10. Nat. Immunol. 2009, 10:981-991.
33. Houghtaling B.R., Cuttonaro L., Chang W., Smith S. A dynamic molecular link between the telomere length regulator TRF1 and the chromosome end protector TRF2. Curr. Biol. 2004, 14:1621-1631.
34. O'Connor M.S., Safari A., Xin H., Liu D., Songyang Z. A critical role for TPP1 and TIN2 interaction in high-order telomeric complex assembly. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:11874-11879.
35. Artandi S.E., DePhino R.A. A critical role for telomeres in suppressing and facilitating carcinogenesis. Curr. Opin. Genet. Dev. 2000, 10:39-49.
36. Hu H., Zhang Y., Zou M., Yang S., Liang X.Q. Expression of TRF1, TRF2, TIN2, TERT, KU70, and BRCA1 proteins is associated with telomere shortening and may contribute to multistage carcinogenesis of gastric cancer. J. Cancer Res. Clin. Oncol. 2010, 136:1407-1414.
37. Bellon M., Datta A., Brown M., Pouliquen J.F., Couppie P., Kazanji M., Nicot C. Increased expression of telomere length regulating factors TRF1, TRF2 and TIN2 in patients with adult T-cell leukemia. Int. J. Cancer 2006, 119:2090-2097.
38. Augereau A., T'kint de Roodenbeke C., Simonet T., Bauwens S., Horard B., Callanan M., Leroux D., Jallades L., Salles G., Gilson E., Poncet D. Telomeric damage in early stage of chronic lymphocytic leukemia correlates with shelterin dysregulation. Blood 2001, 118:1316-1322.
39. Wu X., Amos C.I., Zhu Y., Zhao H., Grossmas B.H., Shay J., Luo S., Hong W.K., Spitz M.R. Telomere dysfunction: a potential cancer predisposition factor. J. Natl. Cancer Inst. 2003, 95:1211-1218.
40. Widmann T.A., Herrmann M., Taha N., König J., Pfreundschuh M. Short telomeres in aggressive non-Hodgkin's lymphoma as a risk factor in lymphomagenesis. Exp. Hematol. 2007, 35:939-946.
41. Wan S.M., Tie J., Zhang Y.F., Guo J., Yang L.Q., Wang J., Xia S.H., Yang S.M., Wang R.Q., Fang D.C. Silencing of the hPOT1 gene by RNA inference promotes apoptosis and inhibits proliferation and aggressive phenotype of gastric cancer cells, likely through up-regulating PinX1 expression. J. Clin. Pathol. 2001, 64:1051-1057.
42. Ramsay A.J., Quesada V., Foronda M., Conde L., Martínez-Trillos A., Villamor N., Rodríguez D., Kwarciak A., Garabaya C., Gallardo M., López-Guerra M., López-Guillermo A., Puente X.S., Blasco M.A., Campo E., López-Otín C. POT1 mutations cause telomere dysfunction in chronic lymphocytic leukemia. Nat. Genet. 2013, 45:526-530.
43. Bechter O.E., Eisterer W., Dlaska M., Kühr T., Thaler J. CpG island methylation of the hTERT promoter is associated with lower telomerase activity in B-cell lymphocytic leukemia. Exp. Hematol. 2002, 30:26-33.
44. Robertson K.D., Wolffe A.P. DNA methylation in health and disease. Nat. Rev. Genet. 2000, 1:11-19.
45. Dessain S.K., Yu H., Reddel R.R., Beijersbergen R.L., Weinberg R.A. Methylation of the human telomerase gene CpG island. Cancer Res. 2000, 60:537-541.
46. Guilleret I., Yan P., Grange F., Braunschweig R., Bosman F.T., Benhattar J. Hypermethylation of the human telomerase catalytic subunit (hTERT) gene correlates with telomerase activity. Int. J. Cancer 2002, 101:335-341.
47. Renaud S., Loukinov D., Abdullaev Z., Guilleret I., Bosman F.T., Lobanenkov V., Benhattar J. Dual role of DNA methylation inside and outside of CTCF-binding regions in the transcriptional regulation of the telomerase hTERT gene. Nucleic Acids Res. 2007, 35:1245-1256.
48. Auchter M., Medves S., Chambeau L., Gazzo S., Moussay E., Ammerlaan W., Morjani H., Géli V., Palissot V., Berchem G., Salles G., Wenner T. Mechanisms of telomere maintenance dysfunction in B-chronic lymphocytic leukemia through CpG island methylation. Blood 2012, 120:3489. (Abstract).
49. Rabinovich G.A., Croci D.O. Regulatory circuits mediated by lectin-glycan interactions in autoimmunity and cancer. Immunity 2012, 36:322-335.
50. Rubinstein N., Alvarez M., Zwirner N.W., Toscano M.A., Ilarregui J.M., Bravo A., Mordoh J., Fainboim L., Podhajcer O.L., Rabinovich G.A. Targeted inhibition of galectin-1 gene expression in tumor cells results in heightened T cell-mediated rejection; a potential mechanism of tumor-immune privilege. Cancer Cell 2004, 5:241-251.
51. Thijssen V.L., Postel R., Brandwijk R.J., Dings R.P., Nesmelova I., Satijn S., Verhofstad N., Nakabeppu Y., Baum L.G., Bakkers J., Mayo K.H., Poirier F., Griffioen A.W. Galectin-1 is essential in tumor angiogenesis and is a target for antiangiogenesis therapy. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:15975-15980.
52. Demydenko D., Berest I. Expression of galectin-1 in malignant tumors. Exp. Oncol. 2009, 31:74-79.
53. Nakajima A., Tauchi T., Sashida G., Sumi M., Abe K., Yamamoto K., Ohyashiki J.H., Ohyashiki K. Telomerase inhibition enhances apoptosis in human acute leukemia cells: possibility of antitelomerase therapy. Leukemia 2003, 17:560-567.
54. Sumi M., Tauchi T., Sashida G., Nakajima A., Gotoh A., Shin-Ya K., Ohyashiki J.H., Ohyashiki K. A G-quadruplex-interactive agent, telomestatin (SOT-095), induces telomere shortening with apoptosis and enhances chemosensitivity in acute myeloid leukemia. Int. J. Oncol. 2004, 24:1481-1487.
55. De Cian A., Lacroix L., Douarre C., Temime-Smaali N., Trentesaux C., Riou J.F., Mergny J.L. Targeting telomeres and telomerase. Biochimie 2008, 90:131-155.
56. Bilsland A.E., Cairney C.J., Keith W.N. Targeting the telomere and shelterin complex for cancer therapy: current views and future perspectives. J. Cell. Mol. Med. 2011, 15:179-186.